HPV-IMPACT Project
Started in 2008, the Human Papillomavirus (HPV) Vaccine Impact Monitoring Project (HPV-IMPACT) monitors rates of high-grade cervical lesions in the United States. Scientists use data from the project to determine the impact of the U.S. HPV vaccination program on cervical precancers caused by HPV. High-grade cervical lesions are precancers that could progress to invasive cervical cancer if left untreated.
HPV-IMPACT has enabled CDC to describe trends in the cervical lesions that could progress to cancer and the reduction of cancer-causing HPV types (such as HPV16 and HPV18) in these cervical lesions.
- From 2008 to 2016, in 20- to 24-year-olds, there were significant reductions in new cervical precancers caused by vaccine-preventable HPV types 16 and 18. There was also a reduction in precancers caused by HPV type 31, a high-risk HPV type not targeted by vaccination, suggesting cross-protection.
- Compared to 2008-2009, cervical precancer rates in 2014-2015 were 50% lower in 18- to 20-year-olds and 36% lower in 21- to 24-year-olds.
- By 2014, the percentage of cervical lesions due to types that are prevented by the HPV vaccine had dropped by 40% among those vaccinated.
- HPV-IMPACT data were used for the first national estimate of CIN2+ cases. We estimated that 196,000 CIN2+ cases were diagnosed in the United States. In 2016, 36% of which were in 18- to 29-year-olds.
HPV-IMPACT includes defined areas in five states covering 1.5 million women
Started in 2008, the Human Papillomavirus (HPV) Vaccine Impact Monitoring Project (HPV-IMPACT) monitors rates of high-grade cervical lesions in the United States. Scientists use data from the project to determine the impact of the U.S. HPV vaccination program on cervical precancers caused by HPV. High-grade cervical lesions are precancers that could progress to invasive cervical cancer if left untreated.
HPV-IMPACT includes defined areas in five states covering 1.5 million women
HPV-IMPACT has enabled CDC to describe trends in the cervical lesions that could progress to cancer and the reduction of cancer-causing HPV types (such as HPV16 and HPV18) in these cervical lesions.
- From 2008 to 2016, in 20- to 24-year-olds, there were significant reductions in new cervical precancers caused by vaccine-preventable HPV types 16 and 18. There was also a reduction in precancers caused by HPV type 31, a high-risk HPV type not targeted by vaccination, suggesting cross-protection.
- Compared to 2008-2009, cervical precancer rates in 2014-2015 were 50% lower in 18- to 20-year-olds and 36% lower in 21- to 24-year-olds.
- By 2014, the percentage of cervical lesions due to types that are prevented by the HPV vaccine had dropped by 40% among those vaccinated.
- HPV-IMPACT data were used for the first national estimate of CIN2+ cases. We estimated that 196,000 CIN2+ cases were diagnosed in the United States. In 2016, 36% of which were in 18- to 29-year-olds.